18+ years in biotechnology or pharmaceutical industry with senior leadership in outsourced manufacturing.
Bachelor's degree in chemistry, engineering, pharmaceutical sciences, or related field; advanced degree preferred.
Proven track record managing small-molecule manufacturing networks and CDMO performance.
Strong technical knowledge of API and drug product manufacturing, analytical development, and process validation.
Experience in establishing CDMO governance and negotiating manufacturing agreements.
Familiarity with NDA/MAA submissions and regulatory approvals.
Strong operational judgment in capacity planning and cost management.
Responsibilities
Lead CMC Technical Operations for Phase III programs and commercial products.
Manage and optimize external manufacturing models with CDMOs and service providers.
Establish partner expectations, governance, and performance metrics.
Oversee CDMO selection, qualification, and relationship management.
Translate corporate priorities into CMC operating plans and budgets.
Own technical operations strategy for mavorixafor, focusing on supply continuity and risk mitigation.
Ensure technical oversight of manufacturing performance and compliance.
Benefits
Opportunity to lead and shape CMC operations for innovative therapies.
Collaborative environment with cross-functional teams and external partners.
Potential for significant impact on product lifecycle and commercial success.
Access to advanced technologies and methodologies in drug manufacturing.
Full Job Description
Accountabilities and Responsibilities:
Lead CMC Technical Operations for X4's Phase III programs and commercial product, with accountability for performance across a fully outsourced API, drug product, analytical testing, and manufacturing network.
Manage and optimize the external manufacturing model, ensuring CDMOs and other service providers deliver against clinical and commercial supply requirements, quality standards, timelines, and budgets.
Establish clear partner expectations, governance, performance metrics, and escalation processes. Hold external partners accountable for execution, issue resolution, and continuous improvement.
Oversee CDMO selection, qualification, capacity planning, and relationship management. Partner with Quality, Legal, Finance, and Supply Chain to establish and manage manufacturing and service agreements.
Translate corporate priorities into annual and long-range CMC operating plans, budgets, and internal resource requirements supporting Phase III execution and reliable commercial supply.
Own the technical operations strategy for mavorixafor, including manufacturing capacity, lifecycle management, supply continuity, cost management, and mitigation of supplier and manufacturing risks.
Oversee external execution of process characterization, technology transfers, process validation, analytical method validation and transfer, stability programs, and ongoing process monitoring, as required for late-stage development and commercial manufacturing.
Ensure appropriate technical oversight of manufacturing performance, deviations, investigations, change controls, and corrective actions in partnership with Quality and external manufacturers.
Partner with Supply Chain & Logistics to align manufacturing schedules, inventory strategies, and external capacity with clinical demand and commercial forecasts.
Proactively assess risks across the outsourced network and implement contingency plans, including alternate suppliers, additional capacity, and technology transfers where appropriate.
Partner with Regulatory and Quality to ensure external partners generate complete, reliable CMC documentation supporting regulatory submissions, inspections, approvals, and post-approval commitments.
Provide technical leadership for CMC regulatory strategy and health authority interactions supporting Phase III programs, commercial expansion, and product lifecycle changes.
Lead and develop a focused internal team capable of directing external partners, evaluating technical recommendations, and making timely, informed decisions.
Represent CMC Technical Operations on Program Teams and X4's Operational Leadership Team, communicating performance, risks, resource needs, and recommendations to support corporate decisions.
Requirements: Proven Experience, Skills and Education:
18+ years of relevant biotechnology or pharmaceutical industry experience, including senior leadership responsibility for outsourced manufacturing supporting Phase III programs and commercial products.
Bachelor's degree in chemistry, engineering, pharmaceutical sciences, or a related scientific or technical discipline; advanced degree preferred.
Demonstrated success managing a fully outsourced small-molecule manufacturing network, with accountability for CDMO performance, technical execution, budgets, and supply continuity.
Strong technical understanding of API and drug product manufacturing, analytical development, process validation, and commercial lifecycle management, with the ability to critically evaluate external partners' recommendations and resolve complex issues.
Proven ability to lead established manufacturing operations while preparing external partners and internal capabilities for late-stage milestones, launches, and commercial growth.
Experience establishing CDMO governance, negotiating manufacturing and service agreements, monitoring performance, and managing partner accountability.
Experience supporting NDA and/or MAA submissions, regulatory approvals, commercial launches, and post-approval CMC activities.
Working knowledge of global cGMP expectations and experience supporting health authority interactions and inspection readiness across external manufacturing sites.
Strong operational and financial judgment, including capacity planning, manufacturing cost management, budgeting, and supply risk mitigation.
Demonstrated ability to build and develop high-performing internal teams and influence external partners and cross-functional colleagues.
Experience contributing to a corporate operational leadership team, aligning technical operations priorities with business objectives and communicating clearly with executive leadership
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases. The company's lead product candidate, mavorixafor, is a potential first-in-class, once-daily, oral inhibitor of CXCR4, currently in Phase 3 development for the treatment of WHIM syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. X4 Pharmaceuticals is also developing X4P-001, a potential first-in-class, oral, small molecule antagonist of CXCR2, currently in Phase 1 development for the treatment of severe congenital neutropenia (SCN), as well as several other preclinical programs.